The paucity of therapeutic choices is a reality often acknowledged by the US Food and Drug Administration (FDA) as it reviews applications for new medical …
The COVID-19 pandemic is creating a $100 billion pharma goliath. Pfizer’s revenue could reach $101.3 billion in 2022, with major contributions coming from the company’s …
Ablynx NV [Euronext Brussels and Nasdaq: ABLX] has announced that results from its Phase III HERCULES study of caplacizumab have been selected as one of only six …
Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.
